Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Investigating norovirus removal by microfiltration, ultrafiltration, and precoagulation-microfiltration processes using recombinant norovirus virus-like particles and real-time immuno-PCR.

Matsushita T, Shirasaki N, Tatsuki Y, Matsui Y.

Water Res. 2013 Oct 1;47(15):5819-27. doi: 10.1016/j.watres.2013.07.004. Epub 2013 Jul 12.

PMID:
23880217
2.

Inhibition of plasma IL-6 in addition to maintenance of an efficacious trough level of infliximab associated with clinical remission in patients with rheumatoid arthritis: analysis of the RISING Study.

Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, Koike T.

Ann Rheum Dis. 2012 Sep;71(9):1583-5. doi: 10.1136/annrheumdis-2011-201069. Epub 2012 May 5. No abstract available.

PMID:
22562980
3.

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis.

Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, Koike T.

Ann Rheum Dis. 2011 Jul;70(7):1208-15. doi: 10.1136/ard.2011.153023. Epub 2011 Apr 8.

4.

Characterization of canine platelet activation induced by platelet activating factor (PAF).

Tsuchiya R, Tatsuki Y, Kitao S, Furuichi M, Neo S, Hisasue M, Yamada T, Kobayashi K.

J Vet Med Sci. 2008 Feb;70(2):181-3.

5.

Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis.

Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, Kamatani N, Harigai M, Ryu J, Inoue K, Kondo H, Inokuma S, Ochi T, Koike T.

Ann Rheum Dis. 2008 Feb;67(2):189-94. Epub 2007 Jul 20.

6.

A determination of bite force in northern Japanese children.

Kamegai T, Tatsuki T, Nagano H, Mitsuhashi H, Kumeta J, Tatsuki Y, Kamegai T, Inaba D.

Eur J Orthod. 2005 Feb;27(1):53-7.

PMID:
15743863
7.

[Effects of long-term administration of tamoxifen on vaginal epithelium and complications of endometrial lesions in breast cancer patients].

Yokosuka K, Teshima H, Katase K, Fujimoto I, Yamauchi K, Hasumi K, Tatsuki Y.

Nihon Sanka Fujinka Gakkai Zasshi. 1995 Feb;47(2):125-32. Japanese.

PMID:
7706853
8.

[Increase in CDDP therapeutic index by lower concentration and longer infusion time--home chemotherapy for ovarian cancer].

Chen JT, Tatsuki Y, Hirai Y, Hasumi K.

Gan To Kagaku Ryoho. 1993 Feb;20(2):265-70. Japanese.

PMID:
8434965
9.

[Multimodal treatment for advanced, ovarian cancer patients with poor performance status--its effectiveness and limitations].

Shimizu Y, Tatsuki Y, Fujimoto I, Yamauchi K, Hasumi K, Masubuchi K.

Nihon Sanka Fujinka Gakkai Zasshi. 1992 Dec;44(12):1551-8. Japanese.

PMID:
1484219

Supplemental Content

Loading ...
Support Center